Emcure Pharma Launches Subsidiary Emcutix Biopharmaceuticals to Expand Derma Portfolio, Targeting $1.84 Bn Indian Dermatology Market

Emcure Pharmaceuticals Ltd, a leading Indian pharma company, has formed a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited, to strengthen its derma portfolio and cater to the growing dermatology segment in India. Emcutix will operate Emcure's existing dermatology business, aiming to significantly expand Emcure’s offerings with a differentiated product portfolio. The Indian dermatology market, currently at $1.84 Bn, is experiencing strong growth due to a growing population and increasing consumer awareness of skin health. Emcure, led by CEO and Managing Director Satish Mehta, aims to address the unmet needs of the Indian market with prescription and consumer dermatology solutions. Emcutix will be headed by G. Sathya Narayanan, who has over three decades of experience in the dermatology sector. Emcutix plans to build a portfolio of products that will make a meaningful difference in skin health in India.